Related Experiment Video

Updated: Jun 3, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

Renato X Santos1, Sónia C Correia, Susana Cardoso

  • 1Department of Life Sciences - Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal.

Journal of Neurochemistry
|March 31, 2011
PubMed

Insights

Rapamycin, an immunosuppressant drug, may extend lifespan and improve memory by inhibiting the Target of Rapamycin (TOR) pathway. This review explores its effects on aging, neuronal plasticity, and Alzheimer's disease.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Neuroscience

Background:

  • Rapamycin is an immunosuppressant used in transplantation.
  • The Target of Rapamycin (TOR) pathway regulates crucial cellular processes like growth, metabolism, and autophagy.
  • TOR exists in two complexes: rapamycin-sensitive TORC1 and rapamycin-insensitive TORC2.

Purpose of the Study:

  • To review evidence linking rapamycin and TOR to lifespan extension.
  • To discuss the role of rapamycin and TOR in memory improvement.
  • To explore recent findings on rapamycin's effects on Alzheimer's disease neuropathology.

Main Methods:

  • Literature review of studies on rapamycin and TOR.
  • Analysis of research on aging, neuronal plasticity, and memory.
  • Examination of studies investigating rapamycin in Alzheimer's disease models.

Main Results:

  • Rapamycin inhibits TORC1, correlating with increased lifespan and decreased protein biosynthesis.
  • Rapamycin demonstrates beneficial effects on neuronal survival and plasticity, enhancing memory.
  • Emerging evidence suggests rapamycin impacts Alzheimer's disease-associated neuropathology.

Conclusions:

  • Rapamycin and the TOR pathway are implicated in aging and lifespan extension.
  • Rapamycin shows potential for cognitive enhancement and memory improvement.
  • Further research into rapamycin's therapeutic applications for neurodegenerative diseases like Alzheimer's is warranted.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze07:07

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze

Published on: October 29, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...